Tokaramide A
Latest Information Update: 23 Apr 2002
Price :
$50 *
At a glance
- Originator Nonindustrial source
- Class Antineoplastics
- Mechanism of Action Cathepsin B inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cancer; Inflammation; Muscular dystrophies
Most Recent Events
- 16 Jun 2000 New profile
- 16 Jun 2000 Preclinical development for Cancer in Japan (Unknown route)
- 16 Jun 2000 Preclinical development for Inflammation in Japan (Unknown route)